Bextra Attorney - FDA Bextra Warnings
These are letters from the FDA and Pfizer issuing warnings and safety alerts for consumers about possible adverse reactions from taking the drug Bextra. This information is a good source to help you understand Bextra and Bextra side effects. If you have been injured by Bextra, your doctor can help you. Then, contact your Bextra Attorney.
Recently released data from controlled clinical trials showing that the COX-2 selective agents (Vioxx, Celebrex, and Bextra) may be associated with an increased risk of serious cardiovascular events (heart attacks and strokes) especially when they are used for long periods of time or in very high risk settings (immediately after heart surgery).
FDA Public Health Advisory Non-Steroidal Anti-Inflammatory Drug Products
The Food and Drug Administration (FDA) issued a Public Health Advisory on December 23, 2004 summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.
FDA Talk Paper on Cox-2 Inhibitors
In 2002, the FDA acknowledged an addition to Bextra's Warnings' section indicating for the possibility of serious skin diseases and allergic reactions to occur and that this drug is now contraindicated with the use of Warfarin.
This is a letter from Pfizer indicating their submission of Bextra's Warnings' section for the possibility of serious skin diseases and allergic reactions to occur and that this drug is now contraindicated with the use of Warfarin.
Weitz & Luxenberg is no longer accepting Bextra cases.
see also:
Bextra Warning Letter on Skin
Bextra Litigation - Bextra Lawyers - Bextra Warning Letter on Skin ReactionsOn November 1, 2002, the department of health and human services officially warned Pharmacia of the dangerous skin related side effects of its drug Bextra. Here is the official warning.
Public Health Advisory NSAID Products
Cox-2 inhibitor Litigation - Vioxx, Bextra, Celebrex Lawers - FDA Public Health AdvisoryPublic Health Advisory Non-Steroidal Anti-Inflammatory Drug Products (NSAIDS)
Labeling
Arthritis Drug Bextra Labeling informationofficial documents on the labeling of the arthritis drug Bextra
